oncteranl logo
  • About
    • Overview
    • Leadership
  • Pipeline
    • Overview
    • ONCT-808
    • ONCT-534
    • Zilovertamab
  • Science
    • Overview
    • Publications
  • Patients
  • Careers
    • Current Opportunities
    • Vision, Mission and Impact
  • Contact

YU ASCO GU 2024 – TIP PHASE 1/2 STUDY OF ONCT-534 in mCRPC

BACK TO HOME

Contact

© 2016 - 2025 Oncternal Therapeutics. All rights reserved

logo
  • About
    • Overview
    • Leadership
  • Pipeline
    • Overview
    • ONCT-808
    • ONCT-534
    • Zilovertamab
  • Science
    • Overview
    • Publications
  • Patients
  • Careers
    • Current Opportunities
    • Vision, Mission and Impact
  • Contact